Sarah Ford | August 11, 2014
Compound Restores Memory Function in Mouse Alzheimer’s Model
Researchers from Yale School of Medicine have discovered a promising new drug compound that reverses some Alzheimer’s effects on memory in mice.
The work directly stems from a 2008-11 BrightFocus grant to Paul Lombroso, MD, who’s on the Yale neurobiology and psychiatry faculty and directs its Laboratory of Molecular Neurobiology. He is senior author of a report published in PLoS Biology August 5.
They found that a protein drug compound, known as TC-2153, blocks the Alzheimer’s disease linked effects of another protein called striatal-enriched tyrosine phosphatase (STEP). At high levels, STEP prevents synaptic strengthening in the brain—something vital to memory function.
It’s actually one of several breakthroughs tied to this BrightFocus grant, which included 2000 Nobel Laureate Paul Greengard, PhD, of Rockefeller University, as coinvestigator. Four years ago…

Get Resources and Insights Straight To Your Inbox
Explore More Articles
Nurturing Payroll Giving Donors: 5 Tips to Deepen Engagement
Payroll giving donors are some of the most consistent and committed supporters nonprofits have, but they’re often overlooked in day-to-day fundraising strategies. These donors contribute…
Read ArticleHow to Align Your Company’s Values with Your Hiring Process
Hiring is about more than filling roles—it’s about shaping the future of your company. Every new team member contributes to the culture you’re building, and…
Read ArticleGet Resources and Insights Straight To Your Inbox
Receive our monthly/bi-monthly newsletter filled with information about causes, nonprofit impact, and topics important for corporate social responsibility and employee engagement professionals, including disaster response, workplace giving, matching gifts, employee assistance funds, volunteering, scholarship award program management, grantmaking, and other philanthropic initiatives.